Related Experiment Videos
Modulation of oestrogen action by receptor gene inhibition
T A Madden1, D Barrow, R A McClelland
1Tenovus Cancer Research Centre, Welsh School of Pharmacy, Redwood Building, King Edward VII Ave, CF10 3XE, Cardiff, UK. maddenta1@cardiff.ac.uk
Abstract:
Selective oestrogen receptor downregulators (SERDs) are a class of highly effective steroidal antitumour agents that reduce cellular levels of the oestrogen receptor (ER). In this study, we compared the efficacy by which three novel molecular approaches: (1) antisense oligonucleotides; (2) antisense RNA; and (3) dominant negative mutants are able to act as SERDs. Using transient and, where appropriate, stable gene transfection experiments we found that constitutive overexpression of ER antisense RNA and a hormone-binding domain compromised dominant-negative ER mutant (DNER-1), were most effective at downregulating ER expression and/or activity in vitro.
Insights
Novel molecular strategies, including antisense RNA and dominant-negative mutants, effectively reduce estrogen receptor (ER) levels. These selective estrogen receptor downregulators (SERDs) show promise for cancer therapy by targeting ER expression and activity.
Area of Science:
- Molecular biology
- Cancer research
- Pharmacology
Background:
- Selective estrogen receptor downregulators (SERDs) are crucial for reducing cellular estrogen receptor (ER) levels.
- Estrogen receptor (ER) signaling plays a significant role in various cancers.
Purpose of the Study:
- To compare the efficacy of three novel molecular approaches as SERDs: antisense oligonucleotides, antisense RNA, and dominant-negative mutants.
- To evaluate the in vitro effectiveness of these agents in downregulating ER expression and activity.
Main Methods:
- Utilized gene transfection experiments (transient and stable) to introduce novel molecular agents.
- Quantified the downregulation of estrogen receptor (ER) expression and/or activity.
Main Results:
- Constitutive overexpression of ER antisense RNA was highly effective in downregulating ER.
- A dominant-negative ER mutant (DNER-1) incorporating a hormone-binding domain also demonstrated significant efficacy in reducing ER levels and activity.
- Antisense oligonucleotides showed less efficacy compared to antisense RNA and dominant-negative mutants.
Conclusions:
- ER antisense RNA and dominant-negative ER mutants (specifically DNER-1) are potent strategies for selective estrogen receptor downregulation.
- These findings support the potential of these novel molecular approaches as therapeutic agents for hormone-dependent cancers.